Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Adma Biologics Inc’s stock clocked out at $21.31, up 0.38% from its previous closing price of $21.23. In other words, the price has increased by $0.38 from its previous closing price. On the day, 2.96 million shares were traded. ADMA stock price reached its highest trading level at $21.46 during the session, while it also had its lowest trading level at $20.54.
Ratios:
To gain a deeper understanding of ADMA’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 49.09 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 45.84. For the most recent quarter (mrq), Quick Ratio is recorded 2.90 and its Current Ratio is at 5.97. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 15 ’25 when Grossman Adam S sold 21,000 shares for $21.46 per share. The transaction valued at 450,660 led to the insider holds 2,055,850 shares of the business.
Grossman Adam S sold 21,000 shares of ADMA for $397,320 on Mar 19 ’25. The President and CEO now owns 2,061,850 shares after completing the transaction at $18.92 per share. On Mar 19 ’25, another insider, Grossman Adam S, who serves as the Director and Officer of the company, bought 84,000 shares for $18.71 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 5083798528 and an Enterprise Value of 5042546688. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.33, and their Forward P/E ratio for the next fiscal year is 21.60. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.87 while its Price-to-Book (P/B) ratio in mrq is 14.45. Its current Enterprise Value per Revenue stands at 11.824 whereas that against EBITDA is 34.297.
Stock Price History:
The Beta on a monthly basis for ADMA is 0.56, which has changed by 2.398724 over the last 52 weeks, in comparison to a change of 0.0635103 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $23.64, while it has fallen to a 52-week low of $5.97. The 50-Day Moving Average of the stock is 17.80%, while the 200-Day Moving Average is calculated to be 22.41%.
Shares Statistics:
It appears that ADMA traded 3.00M shares on average per day over the past three months and 4156350 shares per day over the past ten days. A total of 236.62M shares are outstanding, with a floating share count of 229.31M. Insiders hold about 3.50% of the company’s shares, while institutions hold 86.26% stake in the company. Shares short for ADMA as of 1743379200 were 12963185 with a Short Ratio of 4.32, compared to 1740700800 on 14225572. Therefore, it implies a Short% of Shares Outstanding of 12963185 and a Short% of Float of 5.6199998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
